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Abstract. Little information from clinical trials is available 
regarding the efficacy of trastuzumab treatment in subcen-
timetric breast carcinomas (BCs). The aim of this study 
was to verify the existence of correlations between HER2 
and hormone receptor status, Ki67 values, grade, histotype 
and node involvement in a cohort of pT1a,b BCs from an 
area not widely covered by screening campaigns. A total of 
410 pT1a,b BC formalin‑fixed paraffin‑embedded samples 
collected from eight Sicilian Anatomo‑Pathological Units 
(APUs) were classified according to the WHO classification 
and tumour grading was established. Estrogen and proges-
terone receptor status, Ki67 labelling index and HER2 status 
were available. Relationships between immunohistochemical 
data and clinicopathological characteristics were investigated 
using the Chi‑square test; the cohort was analysed with 
respect to pT1a and pT1b BC as well as to node status. Ductal 
infiltrating carcinoma was the prevalent histotype in the pT1a 
and pT1b stages; G2 was a more common tumour grade, with 
a range between 64.6% and 70% of pT1a and pT1b, respec-
tively. Taking into consideration the lymph node involvement 
of pT1a,b BC, only 17.1% cases were node‑positive without 
a relevant difference between pT1a and pT1b. No significant 
differences between pT1a and pT1b BC cases emerged in 
relation to Ki67 LI, hormone receptors and HER2 status. 
T1a,b BC cases were stratified by node involvement and a 
significant relationship was observed with grade as well as 
with HER2 status. A significant relationship for pT1a cases 
emerged only for tumour grade, while pT1b cases showed 
a significant correlation exclusively with HER2 status. Our 
data clearly support the operative guidelines of the National 
Comprehensive Cancer Network. Therefore, the combined 
treatment with trastuzumab plus chemotherapy should be 
administered only to patients with pT1b or larger BCs. In 
small HER2‑positive pT1a or microinvasive BC, this therapy 
should be considered on a case‑by‑case basis, considering 
tumour grade as the first characteristic.
Introduction
Breast carcinomas (BC) belonging to stage T1 have been 
subdivided with respect to their pathological size in pT1a 
(<5 mm), pT1b (>5 but <10 mm) and pT1c (>10 but <20 
mm) respectively (1). Moreover, the 2005 St. Gallen meeting 
panel classified node‑negative BC as low‑risk according to the 
following criteria: pT ≤2 cm, grade 1, absence of peritumoral 
vascular invasion, patient age >35 years, HER2‑negative 
(2,3). However, certain panel members viewed pT1a and 
pT1b tumours with node‑negative disease as representing low 
risk even when of higher grade and/or occurring in patients of 
younger age (2). There is no overall consensus regarding guide-
lines for the management of patients with stage T1a,bN0M0 
BC and, consequently, clinical decisions should be taken on 
a case‑by‑case basis, accounting for the known prognostic 
clinico-pathological features.
Trastuzumab is currently considered to be the basis of care 
for patients with human epidermal growth factor receptor 2 
(HER2)‑positive BC in either early or advanced cases, as a 
monotherapy or in combination with various therapies (4). 
Certain noteworthy studies have indicated that HER2 overex-
pression/amplification in T1a,bN0M0 BC may be of benefit to 
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clinicians in the decision‑making process (4‑9). On the other 
hand, randomised trials provided no data on small tumours 
(<1 cm) with negative lymph node involvement (7,10). The 
impact of HER2 overexpression in T1a,bN0M0 BC has been 
analysed in two reviews to aid clinicians in the decision‑
making process (5,6). In particular, patients with node‑negative 
HER2‑positive pT1a,b BC have a low risk of recurrence at 
5 years of follow‑up, whereas a less favorable disease‑free 
survival (DFS) was associated with HER2 overexpression in 
patients with hormone receptor‑positive pT1a,bN0 tumours 
(5). Furthermore, patients with HER2‑positive pT1a,bN0M0 
tumours have a significant risk of relapse and should be 
considered for systemic anti‑HER2 adjuvant therapy (6).
In the present study, we have obtained a cohort of 
410 pT1a,b BC in an attempt to verify the existence of 
certain associations between HER2 status, hormone receptor 
status, Ki67 values, grade, histotype and node involvement 
in Sicilian BC patients. In this geographical area, mammo-
graphic screening was introduced in 2000, but has had a poor 
coverage generally limited to specific towns and characterised 
by a low adherence to screening campaigns in comparison to 
the mean value reported in Italy (11). Finally, the emerging 
differences in the neoplastic biology observed between pT1a 
and pT1b were analysed in order to clarify whether treatment 
with trastuzumab plus chemotherapy should be limited only 
to T1b or larger cancer, as currently proposed in the National 
Comprehensive Cancer Network breast cancer guidelines.
Materials and methods
Materials. We collected a cohort of 410 consecutive pT1a,b BC 
cases from eight Sicilian Anatomo‑Pathological Units (APUs), 
obtained from patients who underwent surgery between 2007 
and 2009. The neoplastic samples were gross‑measured in three 
dimensions and the largest diameter measured was considered 
to be the invasive component. Tissue fragments were 10% 
neutral formalin‑fixed for 24‑48 h at room temperature and 
paraffin‑embedded at 56˚C. On 4‑5‑µm haematoxylin‑eosin‑
stained sections, tumours were classified according to the WHO 
histological classification of breast tumours, as modified by 
Rosen and Obermann (12), while tumour grading was estab-
lished according to Elston and Ellis (13).
Methods. For each case, estrogen (ER) and progesterone 
receptor (PR) status and Ki67 labelling index (determined by 
MIB‑1 monoclonal antibody), were available. The threshold 
for ER and PR positivity was >10%, whereas Ki67 overex-
pression was registered when the median value of 13% was 
considered as a cut‑off. To evaluate the inter‑observer agree-
ment, a set of 100 immunostained sections was independently 
re‑evaluated by two expert pathologists (G.N. and G.T.): 
a favourable correlation and reproducibility was obtained 
utilizing kappa statistics. HER2 immunohistochemistry (ICH) 
expression was evaluated using a 1:400 dilution of a poly-
clonal antiserum (code A0485; Dako, Glostrup, Denmark).
Scores. IHC expression was scored by two pathologists as 
follows: 0, no staining or faint membrane staining; 1+, faint 
membrane staining in >10% of tumour cells, incomplete 
membrane staining; 2+, weak to moderate membrane staining 
in >10% of tumour cells; and 3+, intense circumferential 
membrane staining in >10% of tumour cells. For this analysis, 
HER2 scores of 0 and 1+ were considered negative. HER2 
IHC 3+ and fluorescent in situ hybridization (FISH)‑amplified 
tumours were considered positive. IHC 2+ tumours and inde-
terminate tumours were tested for gene amplification by FISH 
(Vysis Path Vision; Abbott, Chicago, IL, USA). Slides were 
hybridised with probes to LSI HER2/neu and CEP17 with the 
Path Vysion HER‑2 DNA Probe Kit (Abbott) according to the 
manufacturer's instructions. Sections were visualised on a fluo-
rescent microscope. Scoring was performed by two pathologists 
according to the manufacturer's guidelines, and the HER2‑
to‑CEP17 ratio was calculated. A HER2‑to‑CEP17 ratio of two 
or greater was considered evidence of gene amplification.
Statistical analysis. The possible correlations between immu-
nohistochemical data and clinico-pathological characteristics 
of pT1a,b BC were investigated using non‑parametric methods 
(Chi‑square test). In particular, we analysed the complete 
cohort in respect to pT1a and pT1b BC as well as to node 
status. Furthermore, each subgroup (pT1a, pT1b) was exam-
ined in relation to pathological and biomolecular parameters 
between node negative or positive cases. P<0.05 was consid-
ered statistically significant. Statistical analysis was carried out 
using the SPSS package (SPSS Inc., Chicago, IL, USA).
Results
In our casuistry, the incidence rate of pT1a,b was 11.3% of all 
BC encountered and histopathologically analysed in Sicilian 
pathological units, with a prevalence of pT1b cases (72.4%). 
Regarding the histotype, the majority of our subcentimetric 
BC was represented by ductal infiltrating carcinomas (80%), 
with an equivalent incidence in pT1a (75.2%) and pT1b 
(81.8%) cases. Moreover, the most widely represented tumour 
grade was G2 (68.5%), with a range between 64.6 and 70% 
of pT1a and pT1b, respectively. These parameters exhibited 
a clearly significant P‑value. Taking into consideration the 
lymph node involvement of pT1a,b BC, only 17.1% cases 
were node‑positive with no significant difference between 
pT1a (14.2%) and pT1b (18.2%).
An adequate immunostaining quality was evident in the 
samples irrespective of the antibody utilised. No significant 
differences between pT1a and pT1b BC cases emerged in 
relation to Ki67 LI, hormone receptors and HER2 status. 
These data are analytically reported in Table I.
When pT1a,b BC cases were stratified by node involve-
ment, a significant relationship was observed for grade 
(P=0.011) as well as HER2 status (P=0.003) (Table II). The 
analysis of each subgroup revealed a significant relationship 
for pT1a cases only for tumour grade (P=0.012) (Table III), 
whereas pT1b cases exhibited a significant correlation exclu-
sively for HER2 status (P=0.002) (Table IV).
Discussion
It has been established that increased expression of HER2 
oncoprotein or its corresponding gene amplification have been 
associated with an aggressive phenotype of BC in terms of 
disease‑free and overall survival (6,14). Nevertheless, in clin-
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ical practice, the treatment of small BC tumours overexpressing 
HER2 remains a field in which numerous controversies have 
been identified. However, the impact of HER2 in tumours 
<1 cm in size requires an adequate examination in relation to the 
hormone receptor subgroups (15), despite the fact that a recent 
study has confirmed that patients with HER2‑positive BC have 
a consistent risk of recurrence, irrespective of hormone receptor 
status (5). Nevertheless, ER/PR status appears to be more valid 
as a predictor of benefit from adjuvant hormonal therapy than 
as a prognostic factor in subcentimetric N0M0 BC (3).
Due to the utilization of breast screening modalities, such 
as digital mammography, the number of T1a,b BC diagnoses 
is increasing and a validation for adjuvant trastuzumab 
therapy in these small breast lesions is required to avoid the 
infrequent health risks, including congestive heart failure, 
also indicated in the subcentimetric BC cohort. The current 
National Comprehensive Cancer Network breast cancer 
guidelines have proposed that treatment with trastuzumab 
plus chemotherapy should generally be limited to patients 
with T1b or larger BC, whereas among patients with T1a or 
smaller carcinomas it is less likely that the trade‑offs of risk 
and benefit require chemotherapy plus trastuzumab (7).
Breast screening in Sicily, the most populous Italian 
region, has only been recently introduced and, generally 
speaking, still exhibits a poor coverage. In particular, in 2000, 
the rate of eligible female (age range 50‑69 years) residents 
in areas covered by the screening campaign was limited to 
5%; three years later, this percentage achieved 10% and, in 
2006, the most recent epidemiological data available, this 
rate reached 27.9% in comparison to the 78.2% of the Italian 
mean (16). In Sicily there are only four breast screening 
programs using mammography, serving the towns of 
Palermo, Catania, Ragusa and Caltanissetta. In 2005, 45,440 
women of 50‑69 years of age and in 2006, 64,161 with the 
same age range were offered screening, obtaining an effec-
tive extension of 22% in comparison to the mean value for 
Italy of 55% (16,17). Finally, in 2006, the correct adhesion in 
Sicily to these breast mammographic screening programs has 
been 35.6% in comparison to the Italian mean of 59.6% (17). 
However, to date, data concerning subgroups of pT1 breast 
invasive carcinomas (a,b,c) from this geographical area are 
not available, since the percentage regarding pT1N0M0 
tumours has been referred only for Catania (28.4%) and 
Palermo (29%) (11).
Table I. Clinico‑pathological and immunohistochemical data of analyzed cohorts.
 pT1a,b (%) pT1a (%) pT1b (%) P‑value
Cases 410 113 (27.6) 297 (72.4) 
Histotype
  CDI 328 (80.0) 85 (75.2) 243 (81.8) 
  CLI 56 (13.7) 12 (10.6) 44 (14.8) 
  CTI 10 (2.4) 6 (5.3) 4 (1.3) <0.001
  CPI 10 (2.4) 8 (7.1) 2 (0.7) 
  CMI 6 (1.5) 2 (1.8) 4 (1.3) 
Grade
  G1 83 (20.2) 34 (30.1) 49 (16.5) 
  G2 281 (68.5) 73 (64.6) 208 (70.0) 0.002
  G3 46 (11.2) 6 (5.3) 40 (13.5) 
Node
  N0 340 (82.9) 97 (85.8) 243 (81.8) NS
  N+ 70 (17.1) 16 (14.2) 54 (18.2) 
Ki67
  Low 285 (69.5) 80 (70.8) 205 (69.0) NS
  High 125 (30.5) 33 (29.2) 92 (31.0) 
ER
  Low 59 (14.4) 16 (14.2) 43 (14.5) NS
  High 351 (85.6) 97 (85.8) 254 (85.5) 
PR
  Low 103 (25.1) 33 (29.2) 70 (23.6) NS
  High 307 (74.9) 80 (70.8) 227 (76.4) 
HER2
  No‑Ampl 356 (86.8) 94 (83.2) 262 (88.2) NS
  Ampl 54 (13.2) 19 (16.8) 35 (11.8) 
NS, no statistical significance. Ampl, amplification.
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In the present study, we have retrospectively analysed 
a cohort of pT1a,b BC consecutively obtained from eight 
APUs not directly involved in breast cancer screening. Since 
clinico‑pathological as well as biomolecular parameters of 
these subcentimetric Sicilian BC were available and stan-
dardised, we have been able to delineate the correlations 
between various prognostic parameters. The rate of pT1a,b 
was 11.3% of all BC encountered in the above‑mentioned 
Sicilian APUs, which was probably mostly dependent on 
opportunistic spontaneous mammography coverage occurring 
Table III. Emerging correlations for pT1a cases.
 pT1a (%) N0 (%) N+ (%) P‑value
Cases 113 (27.6) 97 (85.8) 16 (14.2) 
Grade
  G1 34 (30.1) 34 (35.1) 0 
  G2 73 (64.6) 59 (60.8) 14 (87.5) 0.012
  G3 6 (5.3) 4 (4.1) 2 (12.5) 
Ki67
  Low 80 (70.8) 69 (71.1) 11 (68.8) NS
  High 33 (29.2) 28 (28.9) 5 (31.2) 
ER
  Low 16 (14.2) 15 (15.5) 1 (6.3) NS
  High 97 (85.8) 82 (84.5) 15 (93.7) 
PR
  Low 33 (29.2) 26 (26.8) 7 (43.8) NS
  High 80 (70.8) 71 (73.2) 9 (56.2) 
HER2
  No‑Ampl 94 (83.2) 82 (84.5) 12 (75.0) NS
  Ampl 19 (16.8) 15 (15.5) 4 (25.0) 
NS, no statistical significance. Ampl, amplification.
Table II. Cases of pT1a,b BC stratified by node involvement.
 pT1a,b (%) N0 (%) N+ (%) P‑value
Cases 410 340 (82.9) 70 (17.1) 
Grade
  G1 83 (20.2) 75 (22.1) 8 (11.4) 
  G2 281 (68.5) 233 (68.5) 48 (68.6) 0.011
  G3 46 (11.2) 32 (9.4) 14 (20.0) 
Ki‑67
  Low 285 (69.5) 241 (70.9) 44 (62.9) NS
  High 125 (30.5) 99 (29.1) 26 (37.1) 
ER
  Low 59 (14.4) 49 (14.4) 10 (14.3) NS
  High 351 (85.6) 291 (85.6) 60 (85.7) 
PR
  Low 103 (25.1) 83 (24.4) 20 (28.6) NS
  High 307 (74.9) 257 (75.6) 50 (71.4) 
HER2
  No‑Ampl 356 (86.8) 303 (89.1) 53 (75.7) 0.003
  Ampl 54 (13.2) 37 (10.9) 17 (24.3) 
NS, no statistical significance. Ampl, amplification. 
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at any age. Moreover, a statistically significant difference was 
found between pT1a and pT1b BC in relation to histotype 
and tumour grade, regardless of lymph node involvement. 
On the other hand, no differences were found regarding 
growth fraction and hormone receptor and HER2 status. 
In addition, by stratifying pT1a,b cases in relation to node 
status, a significant association was found between HER2 
overexpression and node metastasis as well as histological 
grade. These data revealed an indirect agreement with data 
reported in a previous study, in which patients with HER2‑
positive tumours of 1 cm or smaller exhibited a high risk of 
relapse and were therefore considered for systemic adjuvant 
trastuzumab therapy (6). However, when we considered each 
pT1 subgroup, a statistically significant correlation emerged 
for HER2 status exclusively in pT1b cases, while the tumour 
grade appeared to be the most significant parameter in 
pT1a BC. Although these latter features were retrospectively 
obtained from a geographical area not widely covered by a 
systematic BC screening campaign, they clearly support the 
operative guidelines of the National Comprehensive Cancer 
Network, which have proposed that combined treatment with 
trastuzumab plus chemotherapy should be administered only 
to patients with pT1b or larger BC. In small HER2‑positive 
pT1a or microinvasive BC, the decision to treat these cancers 
by trastuzumab‑chemotherapy combination should be consid-
ered on a case‑by‑case basis, taking the tumour grade into 
account as the first characteristic as it is one of the most widely 
acknowledged classical histoprognostic characteristics. From 
these results it appears that randomised trials to define treat-
ment for small subcentimetric cancer are required, since the 
low rate of death events as well as casuistries limited to few 
pT1a,b BC samples have represented a bias for oncologists.
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